文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19相关急性呼吸窘迫综合征静脉-静脉体外膜氧合死亡率上升

Increasing Mortality in Venovenous Extracorporeal Membrane Oxygenation for COVID-19-Associated Acute Respiratory Distress Syndrome.
PubMed 文献 · Crit Care Explor · 2022-03-04
一句话结论明尼苏达州多中心前瞻性观察显示,2020年11月至2021年5月接受V-V ECMO的COVID-19相关ARDS患者60天生存率较2020年3月至10月显著下降(41% vs 63%,p=0.026)。

该多中心前瞻性观察研究纳入明尼苏达州4个体外生命支持组织认证的卓越中心自2020年3月至2021年5月因COVID-19相关ARDS接受V-V ECMO的100例患者,比较2020年11月至2021年5月队列(队列2)与2020年3月至10月队列(队列1)的60天生存率。结果示队列2生存率显著低于队列1(41% vs 63%,p=0.026)。合并队列中,非存活者入院至V-V ECMO插管的中位间隔显著长于存活者(10天[6-14天] vs 7天[4-9天],p=0.001),且队列2该间隔显著长于队列1(10天[7-14天] vs 6天[4-10天],p<0.001)。合并队列中未接受类固醇者60天生存率为86%(n=12),接受至少一剂类固醇者为45%(n=39)(p=0.005)。作者认为需进一步研究确定死亡率恶化趋势的原因。

要点

  • 2020年11月至2021年5月接受V-V ECMO的COVID-19相关ARDS患者60天生存率41%,显著低于2020年3月至10月的63%(p=0.026)。
  • 合并队列中,非存活者入院至V-V ECMO插管中位间隔为10天(6-14天),存活者为7天(4-9天),差异显著(p=0.001)。
  • 队列2入院至V-V ECMO插管中位间隔为10天(7-14天),显著长于队列1的6天(4-10天)(p<0.001)。
  • 合并队列中,未接受类固醇者60天生存率为86%(n=12),接受至少一剂类固醇者为45%(n=39),差异显著(p=0.005)。
  • 作者结论认为需进一步研究确定死亡率恶化趋势的原因。

适用人群与场景

  • 2020年3月至2021年5月在明尼苏达州4个体外生命支持组织认证的卓越中心因COVID-19相关ARDS接受V-V ECMO治疗的100例成人患者。

研究设计与关键结果

  • 研究类型为多中心前瞻性观察研究,纳入100例因COVID-19相关ARDS接受V-V ECMO的患者,比较队列2(2020年11月至2021年5月)与队列1(2020年3月至10月)的60天生存率。
  • 主要终点60天生存率:队列2为41%,队列1为63%,队列2显著低于队列1(p=0.026)。
  • 合并队列中,非存活者入院至V-V ECMO插管中位间隔为10天(6-14天),存活者为7天(4-9天),差异显著(p=0.001)。
  • 队列2入院至V-V ECMO插管中位间隔为10天(7-14天),显著长于队列1的6天(4-10天)(p<0.001)。
  • 合并队列中,未接受类固醇者60天生存率为86%(n=12),接受至少一剂类固醇者为45%(n=39),差异显著(p=0.005)。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为需进一步研究确定死亡率恶化趋势的原因;原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Determine the factors associated with mortality in venovenous extracorporeal membrane oxygenation (V-V ECMO) patients with COVID-19 infection and provide an updated report of clinical outcomes for patients treated with V-V ECMO for COVID-19 in Minnesota.

DESIGN: Multicenter prospective observational study.

SETTING: The four adult Extracorporeal Life Support Organization-certified Centers of Excellence in Minnesota.

PATIENTS: A total of 100 patients treated with V-V ECMO for COVID-19-associated acute respiratory distress syndrome (ARDS) from March 2020 to May 2021.

INTERVENTIONS: Not applicable.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was 60-day survival for patients treated with V-V ECMO for COVID-19. Outcomes of patients treated from November 2020 to May 2021(cohort 2) were compared with data from a previous cohort of patients, collected from March 2020 to October 2020 (cohort 1). The data from both cohorts were merged into a single dataset (Combined Cohort). Survival on V-V ECMO due to COVID-19-associated ARDS significantly decreased after October 2020 (63% vs 41%; p = 0.026). The median interval from hospital admission to V-V ECMO cannulation was significantly associated with 60-day mortality (10 d [6-14 d] in nonsurvivors vs 7 d [4-9 d] in survivors; p = 0.001) in the Combined Cohort and was also significantly longer in cohort 2 than cohort 1 (10 d [7-14 d] vs 6 d [4-10 d]; p < 0.001). In the Combined Cohort, the 60-day survival for patients who did not receive steroids was 86% (n = 12) versus 45% (n = 39) for patients who received at least one dose of steroids (p = 0.005).

CONCLUSIONS: There was a significant increase in mortality for patients treated with V-V ECMO for COVID-19-associated ARDS in cohort 2 compared with cohort 1. Further research is required to determine the cause of the worsening trend in mortality.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Braaten JA, Bergman ZR, Wothe JK, et al. Increasing Mortality in Venovenous Extracorporeal Membrane Oxygenation for COVID-19-Associated Acute Respiratory Distress Syndrome. Crit Care Explor. 2022. PMID: 35265853. doi:10.1097/CCE.0000000000000655

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。